Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) emerged from the Wuhan city of China andcame up with a global emergency as a pandemic.It made millions of human lives infected, and thousands of deaths around the globe havealarmedvarious health organizations regarding theurgent need to find out its effectual treatment. Although, at present, there is no treatment or vaccine for this novel coronavirus, there are several drugs under trial to find the most promising one. Remdesivir, a broad-spectrum antiviral drug and hydroxychloroquine, an antimalarial and immunomodulatory drug, have been a matter of interest due to the various researches where they have proved their efficacy against the SARS CoV-2. Here we review the current invitro and invivo evidence of remdesivir and hydroxychloroquine as an effective treatment for SARS CoV-2. Some studies have also been done based on previous experiences of SARS CoV and MERS CoV which share structural similarities with the recent SARS CoV-2 and are also of the same β-coronavirus category. Our finding says, both the drugs have reported to play inhibitory role against SARS coronavirus with very low EC50 values, indicating better potency and less toxicity for future aspects. Although, both the drugs have suggested having beneficial outcomes whether tested on cell lines or few patients tested positive with the virus, however completion and results of clinical trials will prove their potency and efficacy beyond any doubts.